Optimal duration of anticoagulation after venous thromboembolism. - Wikidata - awgldk - TriplyDB

Optimal duration of anticoagulation after venous thromboembolism.

Optimal duration of anticoagulation after venous thromboembolism.

http://www.wikidata.org/entity/Q34781477

about

Should lifelong anticoagulation for unprovoked venous thromboembolism be revisited?Impact of Provoking Risk Factors on the Prognosis of Cerebral Venous Thrombosis in Korean Patients Emergency department ultrasound diagnosis of spontaneous iliopsoas haemorrhage in a patient on warfarin.Pulmonary embolism: risk assessment and management.Optimal treatment duration of venous thrombosis.Managing Extended Oral Anticoagulation After Unprovoked Venous Thromboembolism.Family history of venous thromboembolism (VTE) and risk of recurrent hospitalization for VTE: a nationwide family study in Sweden.Simultaneous appearance of leukemoid reaction and phlegmasia cerulea dolens.

P2860

Q36201247-44F645F0-AF19-47C7-BCE4-D6DD9F14F508 Q36991925-36315799-9120-4260-AB4E-8BEBEC5AAC24 Q37314490-488C496E-EEEC-4E20-8657-B842B9EEB155 Q38042025-6210AD14-4532-4622-BE53-92D9CE0907CC Q38117732-752257BC-7502-47C8-B927-D658CF405890 Q38850540-9C39C548-D308-43FA-A0D2-D3C418EFECC8 Q43468383-27E05A26-D46D-406E-87F3-522E2C3D99B7 Q48193415-449D30A8-40C5-4CD1-B371-5B02F25661C3

P2860

Optimal duration of anticoagulation after venous thromboembolism.

http://www.wikidata.org/entity/Q34781477

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Optimal duration of anticoagulation after venous thromboembolism.

@ast

Optimal duration of anticoagulation after venous thromboembolism.

@en

Optimal duration of anticoagulation after venous thromboembolism.

@nl

type

label

Optimal duration of anticoagulation after venous thromboembolism.

@ast

Optimal duration of anticoagulation after venous thromboembolism.

@en

Optimal duration of anticoagulation after venous thromboembolism.

@nl

prefLabel

Optimal duration of anticoagulation after venous thromboembolism.

@ast

Optimal duration of anticoagulation after venous thromboembolism.

@en

Optimal duration of anticoagulation after venous thromboembolism.

@nl

P1433

Q34781477-05547353-ACE2-40B2-82A0-0C9E1EABC51B

P1476

Q34781477-9260CB39-1825-477B-938F-8602A6B0C8C4

P2093

Q34781477-95220CF9-EB1E-46EF-A423-50E2F0580930

Q34781477-D09DC3B3-DEFC-4DA7-B744-2B4FBE641387

P2860

Q34781477-1D0EDEDF-9513-4F6D-A7C5-7C2B8837FC47

Q34781477-1EC48084-FE75-44A7-8E2B-12F09C826D3F

Q34781477-33AB2A39-25B5-43C3-B59A-8B5A59AA7FC6

Q34781477-4CF230DA-D12F-4C17-877B-31E847700B09

Q34781477-4D57643C-7545-4339-8849-86D370B20EAF

Q34781477-63B1B8B0-5CF0-4B3C-B502-A9D37F4E2A1E

Q34781477-650DE43D-D7ED-46EB-B169-779F21E89EC7

Q34781477-7E9BB572-126A-47D7-A630-7192C7565929

Q34781477-829113D8-898E-4C67-A0D3-F245133BA767

Q34781477-9E6FC38D-98B6-4F64-AEE6-446262AB46A1

P304

Q34781477-FC476D4F-87A4-4878-B593-0CCC5DC76FC7

P31

Q34781477-D3CEA772-1A51-42A8-8535-02BA6C750379

P356

Q34781477-B700890F-F722-4874-BD4E-561DF5F93E48

P407

Q34781477-6A6C1BF5-CEBF-42DF-9C82-0B94C2AE1728

P433

Q34781477-8EDF80AD-FF58-4F65-A206-E1348A5DA801

P478

Q34781477-BA8F9290-9A78-413B-BEE4-03853FD7B0E9

P577

Q34781477-8D3EEBB6-466B-4773-9291-27B84731FFB5

P698

Q34781477-6CD42B01-643A-4055-99F5-917ABD182EBD

P921

Q34781477-D36154FD-C9FB-481F-A976-BBA73C1CC58D

P932

Q34781477-B0572686-E08D-44C6-B438-B434EA64DD25

P356

CIRCULATIONAHA.110.970822

P1433

P1476

Optimal duration of anticoagulation after venous thromboembolism.

@en

P2093

Gregory Piazza

http://www.w3.org/2001/XMLSchema#string

Samuel Z Goldhaber

http://www.w3.org/2001/XMLSchema#string

P2860

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study.

Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.

D-dimer testing to determine the duration of anticoagulation therapy.

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Duration of anticoagulation following venous thromboembolism: a meta-analysis.

Venous thromboembolism: risk factors for recurrence.

Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism.

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

P304

664-667

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.110.970822

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21321182

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation

P932

3074464

http://www.w3.org/2001/XMLSchema#string